Jennifer Yarden

Curewize is an innovative leader in the advancement of personalized treatment of cancers common to children, adolescents and young adults.The ProALL assay family is our lead product, comprised of prognostic and monitoring laboratory tests for tailoring acute lymphoblastic leukemia (ALL) treatment. The Israeli Office of Chief Scientist has approved a grant for the commercialization of ProALL and related products. Curewize possesses: Strong Management: Proven track record and expertise in developing and commercializing biomarker assays together with good business acumen. Competitive Edge: ProALL is markedly better, faster and more cost effective than existing ALL assays. Customer Need: FDA acknowledged a need for improved predictive assays for ALL patients. Market Advantage: Large oncology groups that routinely use predictive tests for planning treatment. Large Pipeline:Development of ProALL for other indications via academic partners clinical specimen bank. I was formerly the Director of Clinical Development at Glycominds with over 15 years experience in the scientific, medical and in vitro diagnostic sectors. I specialize in clinical development and commercialization of in vitro diagnostic and prognostic kits. I hold a Ph.D. in Medical Science from KU Leuven, Belgium; focus is on disease biomarkers and a B.Sc. in Biotechnology cum laude from Tel Chai Academic College, Israel. Specialties: Biomarker Development and Management. Clinical trials design & implementation Analyze & interpret results for product development.Scientific Writing, Biostatistics, Protocol Preparation, Literature Survey, Communication with Investigators and Study Staff, Locating Clinical Sites, Database Management, Analysis, Blood Bank Mangement, SOPs preparation, Immunology, Genetics, Biotechnololgy, Respiratory Diseases, Multiple Sclerosis, Neuroimmunology, Crohn's Disease, Cancer, Biomarkers, Medicine.